Analysts expect PolyPid Ltd. (NASDAQ:PYPD – Get Rating) to post earnings per share of ($0.69) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for PolyPid’s earnings. PolyPid posted earnings of ($0.56) per share during the same quarter last year, which would indicate a negative year over year growth rate of 23.2%. The firm is scheduled to announce its next earnings report on Monday, January 1st.
According to Zacks, analysts expect that PolyPid will report full-year earnings of ($2.41) per share for the current financial year, with EPS estimates ranging from ($2.42) to ($2.39). For the next financial year, analysts expect that the business will report earnings of ($2.11) per share. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research analysts that follow PolyPid.
PolyPid (NASDAQ:PYPD – Get Rating) last posted its earnings results on Wednesday, May 11th. The company reported ($0.63) earnings per share for the quarter, topping the consensus estimate of ($0.64) by $0.01. During the same quarter in the prior year, the business posted ($0.47) earnings per share.
Shares of NASDAQ:PYPD opened at $5.07 on Tuesday. The company has a 50 day moving average of $5.25 and a 200-day moving average of $5.52. The stock has a market cap of $86.42 million, a price-to-earnings ratio of -2.09 and a beta of 0.83. PolyPid has a one year low of $3.92 and a one year high of $9.64.
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Geode Capital Management LLC raised its stake in shares of PolyPid by 12.2% during the third quarter. Geode Capital Management LLC now owns 12,545 shares of the company’s stock valued at $97,000 after acquiring an additional 1,364 shares during the last quarter. Silverarc Capital Management LLC grew its holdings in shares of PolyPid by 1.2% during the first quarter. Silverarc Capital Management LLC now owns 218,175 shares of the company’s stock valued at $1,191,000 after buying an additional 2,555 shares during the last quarter. Morgan Stanley acquired a new position in shares of PolyPid during the second quarter valued at about $32,000. Raymond James Financial Services Advisors Inc. lifted its position in shares of PolyPid by 17.0% during the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 28,499 shares of the company’s stock valued at $164,000 after purchasing an additional 4,138 shares in the last quarter. Finally, Bank of America Corp DE bought a new position in shares of PolyPid during the fourth quarter valued at about $52,000. Institutional investors and hedge funds own 20.84% of the company’s stock.
About PolyPid (Get Rating)
PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs.
- Get a free copy of the StockNews.com research report on PolyPid (PYPD)
- CrowdStrike: A Cybersecurity Unicorn
- Two Stocks You Shouldn’t Buy On Post-Earnings Weakness
- Time to Bid Low for Farfetch Stock
- Texas Roadhouse Stock Looks Sizzling Down Here
- Don’t Wait Too Long to Buy These 3 Mega Caps
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for PolyPid Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PolyPid and related companies with MarketBeat.com's FREE daily email newsletter.